CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

Phase 1 Recruiting 9 enrolled University of Pennsylvania Kite Pharma (a Gilead Company) · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label phase 1 study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous T cells co-expressing two CARs targeting the cryptic EGFR epitope 806 and IL13Ra2 (referred to as "CART-EGFR-IL13Ra2 cells") in patients with newly diagnosed, EGFR-amplified, MGMT-unmethylated glioblastoma, without evidence of disease recurrence/progression following completion of initial radiotherapy.

Timeline

Start: 2025-07-18
Primary completion: 2042-07
Completion: 2042-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CART-EGFR-IL13Ra2 Cells	Cell therapy	—	Other
Background	Cyclophosphamide	Other / unclassified	300 mg/m2	—
Background	Fludarabine	Small molecule	30 mg/m2	—
Background	Rituximab	Monoclonal antibody	375 mg/m2	—

CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy

Summary

Timeline

Drugs

Indications